Cargando…

The nodal positivity rate in breast pCR patients with initially, clinically node-negative breast cancer after neoadjuvant systemic therapy: A systematic review and meta-analysis

BACKGROUND: The axillary lymph node positive (ypN+) rate in patients with clinically node-negative (cN0) breast cancer who have achieved breast pathologic complete response (bpCR) after neoadjuvant systemic therapy (NST) is extremely low, and this population has the potential to be exempt from senti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Le, Chen, Heyan, He, Jianjun, Xie, Peiling, Gao, Pin, Li, Yijun, Zhang, Huimin, Fan, Zhimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090490/ https://www.ncbi.nlm.nih.gov/pubmed/37064127 http://dx.doi.org/10.3389/fonc.2023.1167912

Ejemplares similares

A Novel Risk-Scoring System to Identify the Potential Population Benefiting From Adjuvant Chemotherapy for Node-Negative TNBC Patients With Tumor Size Less Than 1 cm
por: Li, Yijun, et al.
Publicado: (2022)

Evaluation of outcome of chemotherapy for breast cancer patients older than 70 years: A SEER-based study
por: Pu, Shengyu, et al.
Publicado: (2023)

The outcome of neoadjuvant chemotherapy and the current trend of surgical treatment in young women with breast cancer: A multicenter real-world study (CSBrS-012)
por: Li, Yijun, et al.
Publicado: (2023)

Nomogram-derived prediction of pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NCT)
por: Pu, Shengyu, et al.
Publicado: (2020)

A Competing Risk Analysis Model to Determine the Prognostic Value of Isolated Tumor Cells in Axillary Lymph Nodes for T1N0M0 Breast Cancer Patients Based on the Surveillance, Epidemiology, and End Results Database
por: Li, Yijun, et al.
Publicado: (2020)

Establishment and Verification of a Predictive Model for Node Pathological Complete Response After Neoadjuvant Chemotherapy for Initial Node Positive Early Breast Cancer
por: Zhu, Jiujun, et al.
Publicado: (2021)

A nomogram to identify appropriate candidates for breast-conserving surgery among young women with breast cancer: A large cohort study
por: Pu, Shengyu, et al.
Publicado: (2022)

Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

Nomogram Predicts the Role of Contralateral Prophylactic Mastectomy in Male Patients With Unilateral Breast Cancer Based on SEER Database: A Competing Risk Analysis
por: Li, Kunlong, et al.
Publicado: (2021)

Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction
por: Samiei, S., et al.
Publicado: (2019)

The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer
por: Biswas, Tithi, et al.
Publicado: (2017)

Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab
por: Li, Fanfan, et al.
Publicado: (2022)

Effect of the Nipple-Excising Breast-Conserving Therapy in Female Breast Cancer: A Competing Risk Analysis and Propensity Score Matching Analysis of Results Based on the SEER Database
por: Li, Shouyu, et al.
Publicado: (2022)

Is There a Role for Post-Mastectomy Radiotherapy for T1-2N1 Breast Cancers With Node-Positive Pathology After Patients Become Node-Negative Pathology Following Neoadjuvant Chemotherapy?
por: Wang, Qian, et al.
Publicado: (2020)

Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial)
por: Garcia-Tejedor, Amparo, et al.
Publicado: (2023)

Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy
por: Chun, Jung Whan, et al.
Publicado: (2021)

Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

Accuracy of ultrasonographic changes during neoadjuvant chemotherapy to predict axillary lymph node response in clinical node-positive breast cancer patients
por: Li, Zhuoxuan, et al.
Publicado: (2022)

Nomogram for Predicting Lymph Node Involvement in Triple-Negative Breast Cancer
por: Cui, Xiang, et al.
Publicado: (2020)

Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
por: Dey, Nandini, et al.
Publicado: (2021)

Bioinformatics analysis for the role of CALR in human cancers
por: Li, Yijun, et al.
Publicado: (2021)

Neoadjuvant Chemoradiotherapy Does Not Contribute to Worse Survival in Pathological Node-Negative Rectal Cancer
por: Huang, Yong, et al.
Publicado: (2021)

Surgical options of the breast and clinical outcomes of breast cancer patients after neoadjuvant chemotherapy: A single-center retrospective study
por: Sang, Yuting, et al.
Publicado: (2022)

Clinical characteristics and pathologic complete response (pCR) rate after neoadjuvant chemotherapy in postpartum women with breast cancer
por: Dou, He, et al.
Publicado: (2023)

A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
por: Xie, Peiling, et al.
Publicado: (2021)

Development and Validation of a Novel Model for Predicting Prognosis of Non-PCR Patients After Neoadjuvant Therapy for Breast Cancer
por: Yu, Yongqiang, et al.
Publicado: (2021)

A nomogram based on clinicopathological features and serological indicators predicting breast pathologic complete response of neoadjuvant chemotherapy in breast cancer
por: Li, Yijun, et al.
Publicado: (2021)

Tumor Size Still Impacts Prognosis in Breast Cancer With Extensive Nodal Involvement
por: Liu, Yin, et al.
Publicado: (2021)

Artificial neural network models to predict nodal status in clinically node-negative breast cancer
por: Dihge, Looket, et al.
Publicado: (2019)

A Nomogram to Predict Disease-Free Survival Following Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Zhu, Meizhen, et al.
Publicado: (2021)

Multiomics technologies for comprehensive tumor microenvironment analysis in triple-negative breast cancer under neoadjuvant chemotherapy
por: Wang, Gang, et al.
Publicado: (2023)

Survival in Cytologically Proven Node-Positive Breast Cancer Patients with Nodal Pathological Complete Response after Neoadjuvant Chemotherapy
por: Inari, Hitoshi, et al.
Publicado: (2020)

Sentinel Lymph Node Mapping in Breast Cancer: Initial Experience of a Multidisciplinary Team
por: Yasmin, Tahira, et al.
Publicado: (2022)

Para-Aortic Nodal Radiation in the Definitive Management of Node-Positive Cervical Cancer
por: Sanders, Jason C., et al.
Publicado: (2021)

Sentinel Node Identification Rate and Nodal Involvement in the EORTC 10981-22023 AMAROS Trial
por: Straver, Marieke E., et al.
Publicado: (2010)

A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer
por: Bi, Zhao, et al.
Publicado: (2021)

Elevated ADAM-like Decysin-1 (ADAMDEC1) expression is associated with increased chemo-sensitivity and improved prognosis in breast cancer patients
por: Chai, Na, et al.
Publicado: (2023)

Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: da Silva, Jesse Lopes, et al.
Publicado: (2021)

Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer
por: Lv, Zhi-Dong, et al.
Publicado: (2022)

Changing the role of pCR in breast cancer treatment - an unjustifiable interpretation of a good prognostic factor as a “factor for a good prognosis“
por: Ivanovic, Nebojsa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d95s8t0j69l5f9o5k4gafdvruo